Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ARUMM
- Sponsors Celgene Corporation
- 20 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 07 Dec 2015 Last checked against the European clinical Trials database record
- 27 Nov 2015 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020, according to ClinicalTrials.gov record.